Pfizer Inc. $PFE Shares Bought by DAVENPORT & Co LLC

DAVENPORT & Co LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 429,101 shares of the biopharmaceutical company’s stock after purchasing an additional 34,537 shares during the period. DAVENPORT & Co LLC’s holdings in Pfizer were worth $10,925,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the period. PKS Advisory Services LLC raised its stake in shares of Pfizer by 7.0% in the 1st quarter. PKS Advisory Services LLC now owns 13,044 shares of the biopharmaceutical company’s stock worth $327,000 after buying an additional 849 shares in the last quarter. FORA Capital LLC acquired a new stake in shares of Pfizer in the first quarter valued at $439,000. Finally, Epoch Investment Partners Inc. boosted its stake in Pfizer by 2.9% during the first quarter. Epoch Investment Partners Inc. now owns 2,128,420 shares of the biopharmaceutical company’s stock valued at $53,934,000 after buying an additional 59,811 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on PFE. Wolfe Research set a $24.00 target price on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Scotiabank started coverage on shares of Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price objective on the stock. HSBC reiterated a “buy” rating and issued a $29.00 target price on shares of Pfizer in a report on Wednesday, December 10th. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. Finally, Citigroup started coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.06.

Pfizer Stock Performance

Shares of PFE opened at $25.05 on Thursday. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.69. The company has a 50-day moving average of $25.13 and a two-hundred day moving average of $24.88. The stock has a market cap of $142.40 billion, a price-to-earnings ratio of 14.56 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is presently 100.00%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Zacks highlights Pfizer’s strengthened oncology and obesity pipeline as potential drivers of post‑loss‑of‑exclusivity growth, which supports longer‑term revenue upside beyond 2026–2030 LOEs. PFE’s Oncology & Obesity Pipeline Position It for Post-LOE Growth
• Positive Sentiment: Reports that Pfizer is advancing biopharmaceutical operations globally point to improved manufacturing and commercial readiness, which can reduce execution risk for upcoming launches and support margins. Pfizer Inc (NYSE:PFE) Advances Biopharmaceutical Operations Globally
• Neutral Sentiment: Pfizer announced completion milestones in a pediatric Protonix (Phase 2) study — an incremental clinical update investors should watch for data readouts or regulatory next steps, but the item has limited immediate revenue impact until results are reported. Pfizer’s Protonix Pediatric Study Completion: What Investors Should Watch Next
• Negative Sentiment: Pfizer disclosed a patient death in a long‑term hemophilia study (linked to its Hympavzi/marstacimab program), prompting a safety review and reassessment of surgical protocols—this raises potential safety, regulatory and labeling risk that weighs on near‑term sentiment. Pfizer says patient dies after receiving hemophilia drug in trial
• Negative Sentiment: Management set FY‑2025 EPS guidance of $3.00–$3.15 and revenue guidance around $62.0B, both slightly below consensus — a near‑term earnings/revenue miss that increases uncertainty around 2025 results and likely contributed to selling pressure. (Market commentary tying the guidance cut and trial death to a tightened risk/reward is discussed here.) Did a Hympavzi Trial Death and Tighter Guidance Just Reframe Pfizer’s (PFE) Risk–Reward Story?

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.